Pfsl6 is a sexual stage/sporozoite-specific antigen of Plasmodium falciparum and is a potential candidate for a sporozoite-neutralizing vaccine. To obtain more information on the function of Pfsl6 and to investigate its role during transmission and hepatocyte invasion, immunization experiments were performed with both a Pfs 16-specific recombinant vaccinia virus and virus-like particles produced in yeast composed of the hepatitis B surface antigen (HBsAg) and antigen Pfs 16 fused to HBsAg. Upon transformation of yeast cells, harbouring a genomic copy of the HBsAg gene, with a plasmid carrying the fusion gene Pfsl6 -HBsAg (Pfsl6 -S) virus-like hybrid particles composed of HBsAg and Pfsló-S were formed of a size similar to those present in human sera after infection with the hepatitis B virus. Cells infected with recombinant Pfsl6 vaccinia virus synthesized a polypeptide of approx. 16 kDa that reacted with a Pfs 16-specific polyclonal antibody.
Introduction
Sporozoites are the infective stage of the malaria parasite and are found in the salivary glands of female Anopheles mosquitoes. During feeding, mosquitoes inject sporozoites into the host's circula tion which rapidly invade hepatocytes and develop into thousands of merozoites. After rupture of hepatocytes, these merozoites initiate repeated cycles of erythrocyte infection associated with clinical disease. Irradiated sporozoites elicit protective immunity in rodents, monkeys and humans and led to the identifi cation of the circumsporozoite (CS) protein and the sporozoite surface 2 protein (SSP2) [1] [2] [3] [4] [5] . There is now compelling evidence indicating that the immu nity induced by irradiated sporozoites is mediated by anti-sporozoite antibodies, as well as CD4 4-and CD8 + cells that recognize sporozoite-infected hepa tocytes [6 ] . CS protein has been the focus of most efforts to develop a pre-erythrocytic stage malaria vaccine. However, despite many efforts, thus far only a few volunteers have been protected with recombinant or synthetic CS vaccines [7, 8] .
Recently, w e reported the presence of the highly conserved 16-kDa protein P fs l6 on the surface of both sexual-stage parasites and sporozoites [9, 10] . Rabbit sera raised against a synthetic peptide and against recombinant fusion proteins produced in E s cherichia coli recognize a 16-kDa antigen in protein extracts of gametocytes, macrogametes and sporo zoites by Western blot analysis [9] . By one-and two-dimensional Western blot analysis using P fsl6 specific monoclonal antibodies it was demonstrated that these 16-kDa proteins produced by gametocytes and sporozoites are identical (unpublished data). By immunoelectron microscopy, P fs l6 was localized on the surface of sporozoites and in the parasitophorous vacuole membrane of gametocytes [9, 11, 12] .
We further investigated whether P fsl6 is a candi date malaria vaccine antigen that might elicit protec tive antibodies that could neutralize sporozoite infectivity or block transmission. To begin development of suitable P fsl6 vaccines, we report in this study the expression of P fsl6 or P fsl6 fragments, in yeast and mammalian cells. Yeast provides a simple and inex pensive means for recombinant protein production [13] . Very recently, the RTS,S vaccine produced in yeast, containing the hepatitis B virus envelope pro tein as a carrier for B-cell and T-cell epitopes of the central repeat region and the C-terminal region of the CS protein, has proven to be safe and immunogenic during a clinical study conducted in Thailand [14] . Live attenuated viruses, such as vaccinia virus are attractive vectors for vaccine development because they are easily administered, inexpensive to produce and stress-resistant during transport. Vaccinia virus has been used for the production of a large number of antigens from pathogenic organisms, and in sev eral cases vaccination with these recombinant viruses conferred immunity to a subsequent challenge [15, 16] . Viral vectors stimulate different arms of the immune system, which is valuable for vaccine devel opment [17, 18] . Antisera were prepared with both recombinant vaccinia virus and a recombinant P fsl6 fusion pro tein prepared from yeast. These sera were tested for their capacity to inhibit in vitro sporozoite invasion into human hepatoma cells and hepatocytes, and transmission-blocking activity.
Materials and methods

2.L Construction o f recombinant plasmids
Tcd5 / 16-S
Recombinant plasmids were constructed and iso lated by standard methods using E. coli MM294 (F", endAl, thi, hsdR17, supE44, lambda-) as " host" [19] . For the production of Pfs 16-specific fusion proteins in yeast the shuttle vector Tcd5 was used. It contains an expression cassette consisting of the yeast glyceraldehyde-3-phosphate dehydrogenase (TDH3) promoter fused to the gene coding for HBsAg followed by a yeast transcription termination region of the ARG3 gene. The Leu2 gene serves as a selection marker. Both at the 5' and 3' ends of the expression cassette TY1 sequences were inserted [2 0 ] to achieve homologous recombination between the expression cassette and TY1 sequences present within the yeast genome. To create fusions between the Pfsl6 gene and the gene coding for the hepatitis B surface antigen (HBsAg) a PCR fragment coding for amino acids 20-104 of P fsl6 was cloned into the unique Smal site of the shuttle vector Tcd5 (Fig.  1A) . The plasmid containing the P fsl6 sequence was designated Tcd5/16-S. The resulting chimeric gene encodes a protein (P fsl6 -S) of which the deduced amino-acid sequence is shown in Fig. IB. The Tcd5/16-S plasmid was digested with X h o l and the resulting fragments were separated by agarose-gel electrophoresis according to standard procedures [19] . The fragment T cd 5 /1 6 -S "A7toI, containing the TY1, Leu2 and the expression cassette sequences, was then isolated by electroelution [19] . Subsequently, Saccharomyces cerevisiae strain Y1295 (MATa, leu2-3, leu2-112), already contain-4 -5 copies of the HBsAg gene in its genome, was transformed with the Tcd5/16-S-.A7iöI fragment via the spheroplast transformation method described by Hinnen and co-workers [21] . Stable transformants were selected by selection for leucine auxotrophy. 
The transformant containing both a copy of the P fsl6 -S fusion gene and 4 -5 copies of the HBsAg
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Construction o f recombinant vaccinia virus transfer vector p S C ll / 1 6
Transfer vector p S C ll contains a compound early/late promoter of moderate strength, P75, fol lowed by a unique Sm a\ site and flanked by frag ments (TK1 and TKr) of the vaccinia thymidine kinase (TK) gene [22] , It also contains the late vaccinia virus promoter Pn , that is used for the expression of the E. coli lacZ reporter gene. The recombinant P fs l6 specific transfer vector p S C ll/1 6 was constructed via insertion of a PCR fragment, encompassing the complete coding information of P fsl6 , into the unique Smal site. Recombinants were constructed and propagated by standard methods [19] .
For 
Analysis o f the synthesis o f recombinant proteins in yeast
Synthesis of the recombinant proteins P fsl6 -S and HBsAg was monitored by immunoblot analysis of total extracts using rabbit polyclonal antiserum K37S8 (anti-Pfsl6 ) [9] and mouse monoclonal anti body, HBS1 (anti-HBsAg), respectively. Preparation of crude cell extracts and immunoblot analysis was performed as described [24] .
Characterization o f yeast particles containing recombinant Pfs 16-specific fusion protein
HBsAg synthesized in yeast is accumulated in particles similar in size as the 2 2 -nm particles found in human sera after hepatitis B infection which have a buoyant density of 1.18 g cm " 3 [25]. To study whether the recombinant P fsl6 -S fusion proteins and HBsAg synthesized in yeast Y1655 also accumulate in 22 nm particles, crude extracts of Y1655 yeast cells were subjected to CsCl equilibration centrifuga tion as described [24] . In short, crude cell extract, equivalent to approx. 15 mg of cell protein, was mixed with 1,5 M CsCl in sodium phosphate buffer (pH 7,4) and centrifugated in a 50 Ti (Beckman) rotor at 45 000 rpm for 72 h at 8°C. After centrifuga tion 0.5-ml fractions were collected by puncturing the bottom of the tube. Subsequently, 2 p \ of each fraction was analyzed for the presence of HBsAg via the radioimmunoassay AUSRIA II (Abbott Labora tories) and 1 0 fi\ was used for immunoblot analysis to study the presence of the P fsl6 -S fusion protein and HBsAg antigen, utilising antisera K37S8 and HBS1, respectively.
Expression o f gene P fsló using recombinant vaccinia virus vSC U / 1 6
To study the expression of gene Pfsló after infec tion with recombinant vaccinia virus v S C ll/1 6 , a confluent RAT-2 cell monolayer was used. 48 h after infection cells were harvested by low-speed centrifu gation and the pellet fraction was resuspended in 400
jjl\ of SDS/sam ple buffer and heated for 5 min at 95°C. To establish whether a P fsl6 protein of appro priate size was made immunoblot analysis was per formed using K37S8 as antiserum.
Isolation o f gametocytes and sporozoites
Isolation of sporozoites was performed using the urografin gradient method as described by van Pelt and co-workers [26] , Gametocytes were isolated as described [9, 27] . 
Western blot analysis
For Western blot analysis of sporozoite (SWB) and gametocyte (GWB) antigens, samples containing approx. 3 X 106 parasites were boiled for 5 min in 25 fi\ of sample buffer (62.5 mM Tris • H C l/2 % SDS/10% glycerol/5% 2-mercaptoethanol/0.003% Bromophenol blue, pH 7.2). Subsequently, the sam ples were loaded onto a SDS-12.5% polyacrylamide gel and electrophoresis was carried out according to standard methods [19, 28] . The samples were then transferred to nitrocellulose by electroblotting as de scribed [29] . The blot was then washed for 5 min in PBST (phosphate-buffered saline (PBS) supple mented with 0.1% Tween-20) followed by blocking of the unspecific binding sites by incubation for 1 h in PBST buffer supplemented with 3% BSA. Visual ization of the respective antigens was performed as described [9] .
Indirect immunofluorescence assay (IFA)
Sporozoites from salivary glands were counted and diluted to 1000 sporozoites per 10 fi\ of PBS. Drops of 20 fjbl were pipetted in each of the 1 2 wells of multitest slides, air dried and stored at -70°C. Sera were diluted in PBS and 20 p 1 of the appropri ate dilutions were applied to the wells containing sporozoites. After 20 min incubation in a moist chamber at 37°C, the slides were washed thrice with PBS. Fluorescein-conjugated goat anti-rabbit or rab bit anti-mouse IgG antiserum was then added at a dilution of 1:50 (in 0.05% Evans Blue) and the slides were incubated for another 20 min. After an addi tional wash in PBS, 50% glycerol in PBS was added to the samples and they were analyzed by fluores cence microscopy.
Suspension indirect immunofluorescence assay (SIFA)
For SIFA, 100000 sporozoites purified by the urografin gradient method were suspended in 1 0 jjl\ of PBS and incubated at room temperature for 20 min with the appropriate antiserum. Following lowspeed centrifugation the sporozoites were washed twice with 100 fjbl of PBS prior to incubation for 20 min at room temperature with 1 0 pA of goat anti-rabbit or rabbit anti-mouse FITC-conjugated antiserum at a dilution of 1:50 (in 0.05% Evans Blue). After several washings with PBS, samples of 10 ¿¿1 (100000 sporozoites) in PBS were applied to slides and covered by coverslips and they were analyzed by fluorescence microscopy.
Enzyme-linked immunosorbent assay (ELISA)
Microtiter plates were coated with 1 jjLg per well of G ST/B-D , a P fsl6 -encoded polypeptide fused to the C terminus of Schistosoma japonicum glu tathione S-transferase, produced in E. coli [9] . A s says were performed as described [9] . Titers of 1:100 or less were considered negative.
Sporozoite invasion in vitro
Tests of inhibition of sporozoite invasion (ISI) were carried out both with human hepatoma (HepG2-A16) cells and with primary cultures of human hepatocytes, propagated on glass coverslips (diameter 15 mm). Primary cultures of human hepa tocytes were obtained as described previously [30] .
HepG2-A16 cells were grown at 37°C in 5% C 0 2 in air to a confluent monolayer in DMEM supple mented with 2 mM glutam ine/10% fetal calf serum /100 U each of penicillin and streptomycin per ml medium. The culture medium was then re placed by DMEM without supplements and (anti)sera were diluted in the appropriate medium and added to the cell cultures. To the HepG2-A16 cells (350000) and primary human hepatocytes (175000) 30000 and 150000 sporozoites, respectively, were then added per coverslip and incubation was continued for 3 h at 37°C in 5% C 0 2. Subsequently, the coverslips were washed several times with PBS. The cell monolayers were then fixed with methanol ( 1 0 min), followed by three washes with PBS. Penetrated intracellular sporozoites surrounded by a membrane were revealed by an immunoperoxidase antibody assay using a monoclonal antibody to P. falciparum CS (3sp2) as described [26, 31] . All experiments were carried out at least in duplicate.
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Transmission-blocking assay (TB assay)
Mice and rabbit sera were tested for transmission blocking activity in a bioassay by membrane feeding of cultivated gametocytes of NF54 to female mosquitoes in the presence of test or control sera [32],
Immunoelectron microscopy
Immunoelectron microscopy was used to localize the P fsl6 antigen in the exo-erythrocytic stages of P. falciparum. Immunoelectron microscopy was per formed as described [33], R39 was also infected subcutaneously with 107 plaque forming units of the recombinant vaccinia virus and serum was collected 2 2 days after inocula tion (R39v22). As controls, mouse (M2S2) and rab bit (R8S2) antisera raised against recombinant fusion proteins consisting of CS-epitopes and HBsAg pro duced in yeast [13] were used. Pre-sera from mice M2 , M3 and M4 (M1S0) and rabbits R8 , R38, R39,  R57, R64 (R8S0, R38S0, R39S0, R57S0, R64S0) were taken as controls from all mice and rabbits just before the first immunizations. All antisera were used in ELISA, Western blot analysis, IFA, SIFA, TB assay and ISI.
Animals and immunization
Results
Identification o f recombinant proteins synthe sized in yeast
To study the expression of P fsl6 -S and HBsAg in yeast Y1655 cells cellular proteins were analyzed by immunoblot analysis using both a monoclonal anti body HBS1, specific for the HBsAg monomer, and a polyclonal antiserum K37S8, raised against the re combinant P fsló fusion protein produced in E, coli [9] . As shown in Fig. 2 3) . In addition, the density of each fraction was determined. Since for recognition in the AUSRIA II assay the HBsAg antigen must have a native confor mation, the data of Fig. 3A show that fractions 15-20 contain most of the native HBsAg. The aver age buoyant density of the particles present in these fractions was found to be 1.202. To estimate the efficiency of assembly of both HBsAg and P fsl6 -S into 2 2 nm particles, immunoblot analysis of the gradient fractions was also performed with sera HBS1 and K37S8 that recognize linear epitope(s) on the HBsAg and P fsl6 monomers, respectively. Fig. 3B and 3 C show that most of the HBsAg and P fsl6 -S proteins are found in fractions 15-20, demonstrating that the results of the immunoblot analysis follow the data of the AUSRIA II radioimmunoassay (Fig. 3A) .
From the results obtained from the immunological analysis and from the measurements of the refraction indices it can be concluded that the proteins P fsl6 -S and HBsAg assemble into 22-nm particles (P fsl6 -S,S) and as efficient as native HBsAg [25].
Immunogenicity o f P fsl6-S,S particles
To evaluate the immunogenicity of purified P fsl6 -S,S particles, mice and rabbits were immu nized as indicated in Materials and methods. Subse quently, serum samples were analyzed for the pres ence of Pfs 16-specific antibodies by an ELISA. Titers up to 1:16000 were obtained (Table 1) . Western blot analysis showed that sera R38S3 and R39S3 specifi cally reacted with a 16-kDa protein present in total protein extracts of both gametocytes and sporozoites. Serum R8S2, which was raised against yeast parti cles containing HBsAg and CS epitopes, only re acted with the CS protein in a sporozoite Western blot. As indicated in Table 1 , indirect immunofluo rescence assays revealed that all P fsl6 -specific anti- sera reacted with sporozoites in an IFA and fluores cence on the surface was observed when the SIFA was performed with unfixed live sporozoites, al though the intensities were less than obtained after staining with the CS-specific antisera M2S2 and R8S2. As a control, pre-immune sera were used. They did not give any reaction on the Western blots and there was no fluorescense in IFA or SIFA (Table  1) , From these results it can be concluded that as a result of vaccination with the P fsl6 -S,S particles Pfsló-specific antibodies are induced. Moreover, the present study confirms and extends earlier observa tions that the P fsl6 antigen is present on the surface of sporozoites. 
Production o f P fsl6 in recombinant vaccinia virus-infected cells
Expression of the heterologous gene in cells in fected with recombinant vaccinia virus v S C l l / 1 6
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More information about these sera is given in Materials and methods. ISI is expressed as percentage of invasion reduction as compared to the pre-serum. # , number of sporozoites that were able to invade HepG2-A16 cells or primary hepatocytes. was analyzed by Western immunoblots. Western blots were prepared of cell extracts and incubated with Pfsl6 -specific polyclonal antiserum K37S8 [9] . In recombinant vaccinia virus infected cells but not in uninfected cells or in cells infected with wild type virus, a protein with a molecular mass of approx. 16 kDa could be demonstrated (data not shown).
Production o f Pfsl6-specific antisera with re combinant vaccinia virus
To determine whether the vaccinia virus recombi nants were able to induce specific and strong im mune responses to the P fsl6 protein, rabbits were infected twice with recombinant vaccinia virus v S C ll/1 6 . After collection the antisera (R57S2 and R64S2) were first analyzed for the presence of Pfsl 6 -specific antibodies by ELISA. As shown in Table 1 , high antibody titers were reached. Subse quently, the antisera were analyzed for the presence of antibodies reactive to P fsl6 by Western blot analysis of whole lysates prepared from gametocytes and sporozoites (Fig. 4) . As shown in Fig. 4 , West ern blot analysis demonstrated that the antisera R57S2 and R64S2 reacted specifically with the 16-kDa pro tein as present in sporozoites and gametocytes. Fur thermore, IFA and SIFA revealed that the antisera also reacted specifically with antigens present on fixed and live P. falciparum sporozoites (Table 1) , respectively. Moreover, immunoelectron microscopy demonstrated the presence of the P fsl6 antigen at the surface of sporozoites, as well as at the outer surface of exoerythrocytic schizonts collected after invasion of HepG2-A16 cells by sporozoites (Fig. 5) . No reaction was observed with the pre-sera R57S0 and R64S0.
The results of an additional infection of rabbit R39 with recombinant vaccinia virus v S C ll/1 6 sev eral weeks after the third P fsl6 -S,S boost are also presented in Table 2 . The ELISA results showed that a very high Pfs l 6 -specific antibody titer was ob tained when compared to the titers seen after immu nization with P fsl6 -S,S or v S C ll/1 6 alone. Anti serum R39v22 also reacted with the P fsl6 antigen on both a gametocyte and a sporozoite Western blot (Fig. 4) . We could also demonstrate a strong reactiv ity of the serum with the surface of sporozoites in the IFA and SIFA.
Transmission-blocking activity
All mice and rabbit sera were tested for transmis sion-blocking activity in a standard bioassay as de scribed in Materials and methods. None of the anti sera showed transmission-blocking activity.
Inhibition o f sporozoite invasion (ISI) in vitro
We used the inhibition of sporozoite invasion (ISI) into cultured cells assay [31, 34] to investigate whether sera from mice and rabbits vaccinated with yeast P fsl6 -S,S particles and/or recombinant vac cinia virus were able to neutralize sporozoite infectivity. Positive controls were antisera raised in mouse (M2S2) and rabbit (R8S2) against yeast particles containing CS and HBsAg epitopes. Antisera from mice (M3S3 and M4S3) and rabbits (R38S3 and R39S3) immunized with yeast P fs l6 -S,S particles significantly reduced invasion of sporozoites into HepG2-A16 cells, although their capacity to reduce invasion was less than sera to CS protein (Table 2) . However, when primary hepatocytes were used, sera M3S3 and M4S3 were significantly more active than serum M2S2 against CS protein. When sera from rabbits immunized with recombinant vaccinia virus v S C ll/1 6 were tested by ISI, only R57S2 had ISI activity, whereas R64S2 was inactive. However, the rabbit pre-serum R64S0 itself significantly lowered the numbers of invaded sporozoites (Table 2) , which may have obscured R64S2 activity. When rabbit R39 previously immunized with recombinant yeast P fs l6 - (Table 1) . None of the antisera sh ow ed transmission-blocking activity.
S,S particles was boosted with recombinant vaccinia virus v S C ll/1 6 , the ISI activity of this antiserum (R39v22) increased and was similar to rabbit serum R8S2 against CS protein. This correlates with the efficient boosting capacity of the recombinant vac cinia virus shown by anti-Pfsl6 ELISA activities
Discussion
A sporozoite vaccine is expected to block either sporozoite invasion of hepatocytes or its subsequent intrahepatic development. Identification of sporo-zoite ligands might permit development of vaccines that elicit antibodies that block ligand recognition of hepatocyte receptors. It is likely that a series of molecular interactions are critical for sporozoite in vasion. CS protein Region I and Region II, found in both CS protein and TRAP, have been shown to specifically bind to hepatoma cells in vitro, and antibodies to these regions block sporozoite invasion [35] [36] [37] . Recently, van Pelt et al. [26] have suggested that P . falciparum sporozoite invasion of human hepatocytes involves two distinct 20 and 55-kDa membrane proteins, although the sporozoite ligands have not been identified. The results reported here suggest that the highly conserved P fsl6 protein found in both sexual stages and sporozoites [9,10] also might be involved in sporozoite invasion.
To obtain more information on the precise biolog ical function of the 16-kDa protein and to explore its role as a vaccine candidate, immunization studies were performed using recombinant P fsl6 vaccinia virus, and a P fs l6 fragment fused to the HBsAg, and expressed as virus-like particles in the yeast Saccharomyces cerevisiae. In line with previous findings [9] all antisera reacted with a 16-kDa protein in Western blots prepared from gametocyte or sporozoite ex tracts. In the suspension immunofluorescence assay, antibodies to the recombinant P fsl6 product reacted with the surface of the sporozoite, suggesting that these sera recognized the authentic native P fsl6 anti gen. Furthermore, antibodies to the protein con structs specifically reduced in vitro invasion of hu man hepatoma HepG2-A16 cells and primary human hepatocytes. Of interest was our finding that mouse anti-Pfs! 6 antibodies were more active in blocking invasion of human hepatocytes than anti-CS protein antibodies. We have previously demonstrated that sera from human volunteers immunized with CS protein vaccines and protected to sporozoite chal lenge blocked sporozoite invasion of hepatoma HepG2-A16 cells but not human hepatocytes [34] . Thus, P fs l6 may represent a candidate malaria vac cine designed to elicit sporozoite neutralizing anti bodies.
Immunoelectron microscopy experiments using antisera R57S2 and R64S2 from rabbits infected with recombinant vaccinia virus confirm that P fsl6 is localized on the surface of sporozoites (Fig. 5A ) and appears to accumulate between hepatoma cell and the attached sporozoite (Fig. 5B) . We also found that the P fsl6 is localized on newly invaded sporo zoites as well as P. falciparum liver stage parasites. The liver stages are attractive targets [38] [39] [40] for vaccine development because they are susceptible for immune attack for much longer than sporozoites, i.e., at least five days compared to a few minutes [40, 41] . Moreover, both CD4 + and CD8 4 -T cells have been shown to attack malaria-infected hepato cytes, either by direct cytotoxicity or indirectly by cytokines, suggesting that P. falciparum epitopes are expressed on the surface of infected hepatocytes in association with MHC Class-I or -II molecules [40, [42] [43] [44] . The presence of P fsl6 during P. falci parum liver-stage development suggests that P fsl6 vaccines could also elicit cytotoxic T-cell responses directed to P. falciparum-infected hepatocytes.
None of the antisera showed transmission-blocking activity, indicating that P fsl6 probably does not play a critical role in the process of transmission of the parasite from the human host to the mosquito vector. Comparable results were observed in previ ous P fsl6 immunization experiments [9] and this is also in agreement with Baker et al. [11] and Bruce et al. [12] who demonstrated that P fsl6 is located on the parasitophorous vacuole membrane of the game tocyte and not on the plasma membrane of gametes. Since antigens on the gamete plasma membrane are the most likely targets of transmission-blocking anti bodies, the absence or low expression of the P fsl6 antigen on the gamete plasma membrane may ex plain lack of transmission-blocking activity. How ever, the location of P fsl6 on the parasitophorous vacuole membrane suggests that this antigen may play a role during gametocytogenesis or is involved in the emergence of macrogametes from the para sitophorous vacuole membrane. The possible role of P fsl6 in these processes is currently under investiga tion.
In conclusion, the present study confirms that the P fsl6 antigen is expressed on P. falciparum sporo zoites. P fsl6 may be involved in sporozoite invasion of hepatocytes, since Pfs 16-specific antibodies re duced sporozoite invasion into human hepatoma cells and human hepatocytes. Since P fsl6 is also ex pressed during P. falciparum liver-stage develop ment, P fsl6 may represent a candidate antigen for malaria vaccine development.
